Henry Schein, Inc. (NASDAQ:HSIC – Get Free Report) Director Philip A. Laskawy sold 2,604 shares of the stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total value of $184,988.16. Following the completion of the sale, the director now directly owns 24,805 shares of the company’s stock, valued at approximately $1,762,147.20. This represents a 9.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
Henry Schein Stock Performance
Shares of NASDAQ HSIC opened at $69.39 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. The firm has a market cap of $8.62 billion, a price-to-earnings ratio of 28.56, a P/E/G ratio of 2.13 and a beta of 0.90. The business’s 50-day simple moving average is $74.82 and its 200-day simple moving average is $72.61. Henry Schein, Inc. has a 52 week low of $63.67 and a 52 week high of $82.49.
Henry Schein (NASDAQ:HSIC – Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.04). The company had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.25 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The business’s revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.66 EPS. As a group, equities research analysts expect that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.
Institutional Trading of Henry Schein
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on the company. Barrington Research reissued an “outperform” rating and issued a $90.00 price objective on shares of Henry Schein in a research note on Wednesday, February 26th. Wells Fargo & Company began coverage on Henry Schein in a research note on Friday, February 14th. They issued an “equal weight” rating and a $80.00 price objective for the company. Bank of America raised Henry Schein from an “underperform” rating to a “buy” rating and upped their target price for the stock from $69.00 to $84.00 in a research report on Monday, January 6th. UBS Group dropped their target price on Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 26th. Finally, Jefferies Financial Group upped their target price on Henry Schein from $77.00 to $80.00 and gave the stock a “hold” rating in a research report on Thursday, January 23rd. Six equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $81.10.
Get Our Latest Stock Analysis on HSIC
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Featured Articles
- Five stocks we like better than Henry Schein
- How Investors Can Find the Best Cheap Dividend Stocks
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- Dividend Payout Ratio Calculator
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- 3 Fintech Stocks With Good 2021 Prospects
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.